$ARDX Due Diligence — Ardelyx Inc
Strong Buy · 9/10 — full report on Stockato.
- Price: $6.34
- Market cap: $1.6B
- Revenue (TTM): $428M
- Profit margin: -14%
VERDICT: STRONG BUY
SCORE: 9/10
CONFIDENCE: HIGH — based on signal agreement
COMPANY OVERVIEW
Ardelyx Inc is a commercial-stage biopharma focused on kidney and cardiorenal therapies (IBSRELA, XPHOZAH) in the US and select international markets. TTM revenue reached $427.7M with 27.5% YoY quarterly growth; headquarters in Fremont, CA.
KEY FUNDAMENTALS
Revenue TTM $427.7M, gross profit $318.9M, EBITDA –$34M, operating margin –34.7%, P/S 3.68, P/B 10.59. 52-week range $3.55–$8.40. Analyst consensus: 10 buys/1 strong buy, $16.30 target (158% upside). Short interest 10.03% of shares (5.83 days to cover, +5.1% MoM). Forward P/E 40.65.
BULL CASE
- 10 analysts see $16.30 target; 10-yr consensus EPS NPV $6.92–$12.33/share at 12.5–25% discount rates vs $6.345 price.
- Q1 sales $94.5M beat estimates; IBSRELA FY guidance repeatedly exceeded (e.g., $145–150M raised to $158.3M actual).
- BULLISH_FLOW: 77% bullish premium ($704K calls vs $207K puts) across 30 alerts.
- Trademark filings in Canada/EU signal international expansion; management credibility 9/10 with no goalpost shifts.
BEAR CASE
- Still unprofitable (EPS –$0.24, profit margin –13.6%); EV/EBITDA 130.9x.
- XPHOZAH Medicare Part D reimbursement loss from 2025 creates ongoing gross-to-net pressure.
- Short interest 10.03% with recent increase; volume today only 0.2× 20-day average.
- RSI 78 signals short-term overbought; price near Bollinger upper band ($6.44).
OPTIONS POSITIONING
BULLISH_FLOW with 77% bullish premium = $704.3K calls vs $207.3K puts across 30 alerts, net +$497K directional. Top trades: $133k BOUGHT CALL $7 2026-06-18; $98k BOUGHT CALL $6 2026-08-21 SWEEP; $70k BOUGHT CALL $7 2026-06-18; $54k SOLD CALL $7 2026-06-18 SWEEP; $45k BOUGHT CALL $7 2026-05-15. IV skew neutral. Flow aligns with bullish fundamental and X narrative.
X / SOCIAL CHATTER
@NightOwlBiotech notes ARDX revenue multiples are lowest among commercial-stage non-oncology peers and 10-yr EPS NPV implies >2× upside. @scott_jenn63528 flags June Canada/EU trademark filings as under-the-radar expansion prep. @RLew1129 continues adding ARDX on dips as a core small-cap bio holding alongside XERS/TGTX.
MANAGEMENT CREDIBILITY
9/10 trajectory rating. Hit or exceeded IBSRELA guidance in all tracked quarters (Q2–Q4 2024) while transparently managing XPHOZAH reimbursement risk without excuses or goalpost moves; 23 routine insider sales viewed as 10b5-1 diversification.
KEY CATALYSTS
Q2 earnings (late July), potential CIC label expansion, EU/Canada trademark progress, short-covering above $6.47 resistance.
KEY RISKS
Reimbursement headwinds on XPHOZAH, continued dilution risk, macro biotech funding environment.
BOTTOM LINE
At 3.7× sales with $16.30 analyst target and 77% bullish options flow, ARDX offers asymmetric upside on proven commercial execution; add on dips toward $5.80–$6.00 support.
How ARDX trades
59% below its 52-week high; worst drawdown in the past year 59%.
Moved 14.7% on average (absolute) across the last 8 earnings reports.
Behind SPY by 44.5 pts over 3 months.
Trades as a low-beta name: β 0.5 to QQQ, 4.7× SPY's volatility.
Realized volatility is 32% over 20 days, calmer than its 1-year 61%.
One-year beta: 0.83 to SPY, 0.46 to QQQ (data-vendor beta 0.68).
Correlation of daily returns: SPY 0.08 (60 days) / 0.18 (1 year); QQQ 0.12 (60 days) / 0.15 (1 year); IWM 0.16 (60 days) / 0.3 (1 year); XBI 0.27 (60 days) / 0.35 (1 year); 10y yield (daily change) -0.06 (60 days) / -0.03 (1 year).
Realized volatility: 32% (20 days), 46% (60 days), 61% (1 year).
Maximum drawdown over the past year -59%; -59% from the 52-week high.
ARDX options and volatility
ATM implied vol runs 57% at 43 days to 66% at 190 days (contango).
Options price 1.80× the last 20 days' realized volatility — rich.
The first expiry after earnings (2026-11-20, 43 days out) prices ±16.7%, which also covers 43 days of ordinary movement; the average move on earnings day itself has been 14.7%.
Dealers are short gamma; call wall 3.0, put wall 3.0.
Options-implied expected moves: earnings expiry (2026-11-20): ±$0.55 (±16.72%).
Options data as of 2026-10-08 07:13 UTC.